Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a mid-size sponsor after a complete response letter, a DSMB note on an imbalance that is not yet a signal put biosimilar analytical similarity report in play. Pharmacovigilance medical reviewer should decide whether the 505(b)(2) bridge is legally and scientifically enough without filling gaps biosimilar analytical similarity report does not contain.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a DSMB note on an imbalance that is not yet a signal is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a DSMB note on an imbalance that is not yet a signal; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. 4. Biosimilar analytical similarity report is missing the fact pharmacovigilance medical reviewer needs after a DSMB note on an imbalance that is not yet a signal; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 2. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in biosimilar analytical similarity report, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Owner and next date for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter - What changes the 505(b)(2) bridge is if a DSMB note on an imbalance that is not yet a signal is later withdrawn